公开(公告)号：US20230346903A1

公开(公告)日：2023-11-02

申请号：US18060779

申请日：2022-12-01

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G.K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/09 ,  C07K16/12 ,  C07K16/44 ,  A61K39/39 ,  A61K39/40 ,  A61K47/10 ,  A61K47/26

CPC classification number: A61K39/092 ,  C07K16/1275 ,  C07K16/44 ,  A61K39/39 ,  A61K39/40 ,  A61K47/10 ,  A61K47/26 ,  A61K2039/505

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US20210371453A1

公开(公告)日：2021-12-02

申请号：US17400938

申请日：2021-08-12

Applicant: Pfizer Inc.

Inventor： Mingming Han ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad

IPC: C07K1/107 ,  C07K14/34 ,  C07K14/22 ,  C07K14/315 ,  A61K39/095 ,  A61K39/09 ,  A61K47/64 ,  C07H3/06

Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US20210145957A1

公开(公告)日：2021-05-20

申请号：US17161119

申请日：2021-01-28

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G.K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/09 ,  C07K16/12 ,  C07K16/44 ,  A61K39/39 ,  A61K39/40 ,  A61K47/10 ,  A61K47/26

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US20200246448A1

公开(公告)日：2020-08-06

申请号：US16774309

申请日：2020-01-28

Applicant: PFIZER INC.

Inventor： Jianxin Gu ,  Jin-hwan Kim ,  Avvari Krishna Prasad ,  Yu-ying Yang

IPC: A61K39/095 ,  A61K47/64 ,  A61K45/06 ,  A61K39/09

Abstract: The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US10392420B2

公开(公告)日：2019-08-27

申请号：US14652723

申请日：2013-12-13

Applicant: Pfizer Inc.

Inventor： Mingming Han ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad

IPC: C07K1/107 ,  C07K14/34 ,  C07K14/22 ,  C07K14/315 ,  A61K39/095 ,  A61K39/09 ,  C07H3/06 ,  A61K47/64 ,  A61K39/00

Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US20190000953A1

公开(公告)日：2019-01-03

申请号：US16133021

申请日：2018-09-17

Applicant: Pfizer Inc.

Inventor： Jianxin Gu ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad ,  Yu-Ying Yang

IPC: A61K39/09 ,  A61K39/39 ,  A61K39/385 ,  A61K39/00

Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.

公开(公告)号：US10105431B2

公开(公告)日：2018-10-23

申请号：US15110634

申请日：2015-01-15

Applicant: Pfizer Inc.

Inventor： Jianxin Gu ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad ,  Yu-Ying Yang

IPC: A61K45/06 ,  A61K47/00 ,  A61K39/09 ,  A61K39/385 ,  A61K39/39 ,  A61K39/00

Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.

公开(公告)号：US09950058B2

公开(公告)日：2018-04-24

申请号：US15385611

申请日：2016-12-20

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  C07K14/135 ,  C12N15/01 ,  C07K14/005 ,  C12N7/00 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K2039/575 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/70 ,  C07K2319/735 ,  C12N7/00 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US20240374699A1

公开(公告)日：2024-11-14

申请号：US18531055

申请日：2023-12-06

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/09 ,  A61K39/00 ,  A61K47/64

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

公开(公告)号：US12128095B2

公开(公告)日：2024-10-29

申请号：US17672126

申请日：2022-02-15

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  A61K39/00 ,  A61P31/04 ,  A61P37/04 ,  C08B37/00

CPC classification number: A61K39/0258 ,  A61P31/04 ,  A61P37/04 ,  C08B37/006 ,  A61K2039/6037 ,  A61K2039/627

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.